Abstract 1995
Background
Anti-PD-1 and anti-CTLA-4 immunotherapies have become the standard of care for metastatic melanoma. However, the majority of patients develop resistance to therapy. Macrophages are abundant cells in tumours, but their role in immunotherapy response and resistance is largely unknown. This study investigated the role of macrophages in anti-PD-1 +/- CTLA-4 response in stage IV melanoma patients.
Methods
Transcriptomic and multiplex immunohistochemistry (mIHC) immune profiling were performed on formalin-fixed paraffin embedded tissue pre-treatment biopsies from advanced melanoma patients treated with anti-PD-1 (n = 19) or anti-PD-1 + anti-CTLA-4 (n = 10). Response and progression-free survival were assessed using RECIST criteria. Using tumour dissociates, mass cytometry was used to characterize macrophages in detail.
Results
Although there was no significant difference in CD68+ macrophages between responding and non-responding patients, responding patients had a significantly higher intratumoral density of CD14+ CD68+ CD16+ macrophages compared to non-responders at baseline (median= 192 versus 23; p = 0.006). Using mIHC, patients were classified into high/low CD16+ macrophages and differential RNA expression analysis was performed. CD16+ high macrophage tumours displayed increased expression of genes related to T cell activation (TIGIT, LAG3, ICOS, PDCD1, FASLG and TBX21), MHC class I presentation (TAP1, UBD, PSMB10 and B2M) and chemokine + cytokine activity (CXCL13, CXCL10, CXCL11, CXCL9, CXCR6 and CXCR3). Using mass cytometry, we determined that CD16+ macrophages are CD13+ HLA-DR+, ICOS+ CD86+/- LAG3- GITR- TIGIT-. Multivariate analysis showed that low LDH, low melanoma substage and the presence of high CD16+ macrophages were associated with a significantly better overall response rate (OR = 14; p = 0.011) and progression free survival (HR = 0.15; p = 0.016), but not overall survival (HR = 0.22; p = 0.068).
Conclusions
Presence of CD68+ CD14+ CD16+ macrophages in pre-treatment melanoma combined with low LDH and low melanoma substage strongly correlates with response and survival of advanced melanoma patients treated with immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
James Wilmott.
Funding
National Health and Medical Research Council (NHMRC).
Disclosure
M.S. Carlino: Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. G.V. Long: Advisory / Consultancy: Amgen; Advisory / Consultancy: Array; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract